Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma

International Journal of Cancer

Volumn 134, Issue 5, 2014, Pages 1112-1122

  Dewaele, Barbara ^a   Przybyl, Joanna ^a,b,c   Quattrone, Anna ^a   Finalet Ferreiro, Julio ^a   Vanspauwen, Vanessa ^a   Geerdens, Ellen ^d   Gianfelici, Valentina ^d   Kalender, Zeynep ^d   Wozniak, Agnieszka ^a   Moerman, Philippe ^a   Sciot, Raf ^a   Croce, Sabrina ^e   Amant, Frederic ^a   Vandenberghe, Peter ^a   Cools, Jan ^d   Debiec Rychter, Maria ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e INSTITUT BERGONIÉ   (France)

Author keywords

CXorf67; endometrial stromal sarcoma; fusion; MBTD1

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CARCINOGENESIS; CASE REPORT; CHROMOSOME BANDING PATTERN; CHROMOSOME TRANSLOCATION X; CXORF67 GENE; CYTOGENETICS; ENDOMETRIUM SARCOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION PROFILING; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; MBTD1 GENE; MIDDLE AGED; OPEN READING FRAME; PRIORITY JOURNAL; RNA SEQUENCE;

CXORF67; ENDOMETRIAL STROMAL SARCOMA; FUSION; MBTD1;

ADULT; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, X; COMPARATIVE GENOMIC HYBRIDIZATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE FUSION; HUMANS; MIDDLE AGED; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; RECURRENCE; SARCOMA, ENDOMETRIAL STROMAL; TRANSLOCATION, GENETIC;

EID: 84890551619     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28440     Document Type: Article

References (51)

1. Tavassoli FA, Devilee P, eds. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003. 432 p.
2. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 2001; 98: 6348-53.
3. Chiang S, Oliva E,. Recent developments in uterine mesenchymal neoplasms. Histopathology 2013; 62: 124-37.
4. Micci F, Panagopoulos I, Bjerkehagen B, et al. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 2006; 66: 107-12.
5. Panagopoulos I, Micci F, Thorsen J, et al. Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. PLoS One 2012; 7: e39354.
6. Chiang S, Ali R, Melnyk N, et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol 2011; 35: 1364-72.
7. D'Angelo E, Ali RH, Espinosa I, et al. Endometrial stromal sarcomas with sex cord differentiation are associated with PHF1 rearrangement. Am J Surg Pathol 2013; 37: 514-21.
8. Panagopoulos I, Thorsen J, Gorunova L, et al. Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. Genes Chromosomes Cancer 2013; 52: 610-18.
9. Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10: 1188-98.
10. Lee CH, Ou WB, Marino-Enriquez A, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci USA 2012; 109: 929-34.
11. Lee CH, Ali RH, Rouzbahman M, et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol 2012; 36: 1562-70.
12. Amant F, Moerman P, Cadron I, et al. Endometrial stromal sarcoma with a sole t(X;17) chromosome change: report of a case and review of the literature. Gynecol Oncol 2003; 88: 459-62.
13. Shaffer LG, McGowan-Jordan J, Schmid M, eds. An international system for human cytogenetic nomenclature. Basel: Karger, 2013. 140 p.
14. Dewaele B, Floris G, Finalet-Ferreiro J, et al. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 2010; 70: 7304-14.
15. Hu J, Ge H, Newman M, et al. OSA: a fast and accurate alignment tool for RNA-Seq. Bioinformatics 2012; 28: 1933-4.
16. McPherson A, Hormozdiari F, Zayed A, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011; 7: e1001138.
17. Kakuno Y, Yamada T, Mori H, et al. Establishment and characterization of a cell line (OMC-9) originating from a human endometrial stromal sarcoma. Hum Cell 2008; 21: 46-55.
18. Taguchi T, Sonobe H, Toyonaga S, et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest 2002; 82: 663-5.
19. Eryilmaz J, Pan P, Amaya MF, et al. Structural studies of a four-MBT repeat protein MBTD1. PLoS One 2009; 4: e7274.
20. Lanzuolo C, Orlando V,. Memories from the polycomb group proteins. Annu Rev Genet 2012; 46: 561-89.
21. Benoit YD, Laursen KB, Witherspoon MS, et al. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. J Cell Physiol 2013; 228: 764-72.
22. Margueron R, Reinberg D,. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-9.
23. Sauvageau M, Sauvageau G,. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
24. Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012; 26: 651-6.
25. Vissers JH, van LM, Citterio E,. The emerging role of Polycomb repressors in the response to DNA damage. J Cell Sci 2012; 125: 3939-48.
26. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-43.
27. Czermin B, Melfi R, McCabe D, et al. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002; 111: 185-96.
28. Kuzmichev A, Nishioka K, Erdjument-Bromage H, et al. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002; 16: 2893-905.
29. Muller J, Hart CM, Francis NJ, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002; 111: 197-208.
30. Hong Z, Jiang J, Lan L, et al. A polycomb group protein, PHF1, is involved in the response to DNA double-strand breaks in human cell. Nucleic Acids Res 2008; 36: 2939-47.
31. Klymenko T, Papp B, Fischle W, et al. A Polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysine-binding activities. Genes Dev 2006; 20: 1110-22.
32. Oktaba K, Gutierrez L, Gagneur J, et al. Dynamic regulation by polycomb group protein complexes controls pattern formation and the cell cycle in Drosophila. Dev Cell 2008; 15: 877-89.
33. Simon JA, Kingston RE,. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10: 697-708.
34. Bonasio R, Lecona E, Reinberg D,. MBT domain proteins in development and disease. Semin Cell Dev Biol 2010; 21: 221-30.
35. Boccuni P, MacGrogan D, Scandura JM, et al. The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). J Biol Chem 2003; 278: 15412-20.
36. Grimm C, de Ayala Alonso AG, Rybin V, et al. Structural and functional analyses of methyl-lysine binding by the malignant brain tumour repeat protein Sex comb on midleg. EMBO Rep 2007; 8: 1031-7.
37. Kalakonda N, Fischle W, Boccuni P, et al. Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1. Oncogene 2008; 27: 4293-304.
38. Trojer P, Li G, Sims RJ, III, et al. L3MBTL1, a histone-methylation- dependent chromatin lock. Cell 2007; 129: 915-28.
39. Wismar J, Loffler T, Habtemichael N, et al. The Drosophila melanogaster tumor suppressor gene lethal(3)malignant brain tumor encodes a proline-rich protein with a novel zinc finger. Mech Dev 1995; 53: 141-54.
40. Wu S, Trievel RC, Rice JC,. Human SFMBT is a transcriptional repressor protein that selectively binds the N-terminal tail of histone H3. FEBS Lett 2007; 581: 3289-96.
41. Botuyan MV, Lee J, Ward IM, et al. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 2006; 127: 1361-73.
42. Schotta G, Sengupta R, Kubicek S, et al. A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev 2008; 22: 2048-61.
43. Behbahani TE, Kahl P, von der GJ, et al. Alterations of global histone H4K20 methylation during prostate carcinogenesis. BMC Urol 2012; 12: 5.
44. Yu P, Ma D, Xu M,. Nested genes in the human genome. Genomics 2005; 86: 414-22.
45. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-3.
46. Gudmundsson J, Sulem P,. Genetic variants contributing to risk of prostate cancer. EP2522743A2. 2012.
47. Manolio TA,. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010; 363: 166-76.
48. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-15.
49. Li H, Ma X, Wang J, et al. Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival. Proc Natl Acad Sci USA 2007; 104: 20001-6.
50. Oliva E, Young RH, Amin MB, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002; 26: 403-12.
51. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050-63.